{"filings":[{"id":95891,"accession_number":"0001193125-26-210298","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Monte Rosa Q1 net loss $44.5M; cash $671M; multiple pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $44.5M vs net income of $46.9M in Q1 2025; collaboration revenue fell to $4.2M from $84.9M.","Cash, equivalents, and securities total $671.2M as of March 31, 2026, sufficient into 2029; $345M public offering closed in Jan.","MRT-8102 (NEK7 MGD) showed 85% CRP reduction in elevated CVD risk; Phase 2 studies in ASCVD, gout, and hidradenitis suppurativa planned H2 2026–H1 2027.","MRT-2359 (GSPT1 MGD): Phase 2 in mCRPC with AR mutations anticipated Q3 2026 after positive interim data; supply deal with Johnson & Johnson.","Novartis to initiate multiple Phase 2 studies of MRT-6160 (VAV1 MGD) in immune-mediated diseases in 2026; Monte Rosa eligible for up to $2.1B milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":4210000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109289,"accession_number":"0001193125-26-109353","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Monte Rosa posts Q4 net loss $46.1M; cash runway into 2029; positive Phase 1 data for NEK7 degrader MRT-8102","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $46.1M vs $13.4M in Q4 2024; full-year net loss decreased to $38.6M from $72.7M.","Cash, equivalents, securities $382.1M at Dec 31, 2025; $345M Jan 2026 offering extends runway into 2029.","Interim Phase 1 data for NEK7 degrader MRT-8102: 85% CRP reduction in elevated CVD-risk subjects; unblinded safety shows no SAEs.","Plans to initiate multiple Phase 2 studies of MRT-8102 in H2 2026 (ASCVD, gout, hidradenitis suppurativa).","MRT-2359 in mCRPC with AR mutations: 100% PSA response rate; Phase 2 with apalutamide planned Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109288,"accession_number":"0001193125-26-044616","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Monte Rosa Therapeutics PAO Edmund Dunn to retire; Matthew Bowen appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Edmund Dunn, SVP, Corporate Controller and PAO, to retire effective April 3, 2026; no severance or disagreement.","Matthew Bowen, age 37, promoted from Director, Finance to Corporate Controller and PAO effective April 3, 2026.","Bowen joined Monte Rosa in June 2021 post-IPO; previously 7 years at Ernst & Young in audit.","Bowen holds BS and MS in Accounting from Bryant University and is a licensed CPA in Massachusetts.","No family relationships or related party transactions with Bowen; no arrangements for promotion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109287,"accession_number":"0001193125-26-009005","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Monte Rosa prices $300M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 11,125,000 shares at $24.00/share and pre-funded warrants for 1,375,000 shares at $23.9999 each.","Gross proceeds ~$300M; estimated net ~$281.6M after discounts and expenses.","Underwriters granted 30-day option to purchase up to 1,875,000 additional shares.","Proceeds to fund MRT-8102 for atherosclerotic cardiovascular disease, QuEEN platform development, and working capital.","Expects cash runway into 2029; closing expected on or about January 12, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109286,"accession_number":"0001193125-26-006341","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Monte Rosa Therapeutics terminates ATM stock sale program; no further sales until new prospectus filed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective January 7, 2026, company terminated the ATM prospectus under its shelf registration.","No further sales of common stock under the Sales Agreement unless new prospectus filed.","As of termination date, 2,955,082 shares sold for net proceeds of $24.2 million.","Sales Agreement with Jefferies remains in effect but no sales currently authorized.","Reason for termination not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109285,"accession_number":"0001193125-26-005420","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Monte Rosa reports positive interim Phase 1 data for MRT-8102; hsCRP reduced 85% in 4 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In subjects with elevated CVD risk, MRT-8102 reduced hsCRP by 85% after 4 weeks; 94% achieved hsCRP <2 mg/L (median baseline 6.3 mg/L).","NEK7 degradation ~80-90% in T cells across all dose levels (5-400 mg); favorable safety with mild/moderate AEs, no dose dependency.","Median IL-6 dropped 55% to below cardiovascular risk threshold; CSF IL-6 decreased 75% in two subjects, suggesting CNS effect.","Plan to initiate Phase 2 GFORCE-2 study in ASCVD in 2026; expand GFORCE-1 with readout H2 2026.","Also evaluating Phase 2 studies in MASH, gout, recurrent pericarditis; collaborator Novartis to initiate Phase 2 studies of MRT-6160 in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125783,"accession_number":"0001193125-25-319981","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MRT-2359 + enzalutamide shows 100% PSA response in AR-mutant mCRPC; Phase 2 planned 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In 14 evaluable mCRPC patients, overall DCR 64% (9/14); in AR-mutant subset (n=4), 100% PSA response rate and 100% DCR, with 2 RECIST partial responses.","Combination well tolerated with primarily Grade 1-2 GI adverse events; no new safety signals.","Company plans to initiate Phase 2 study of MRT-2359 + AR inhibitor targeting AR-mutant mCRPC patients in 2026.","Breast cancer cohort (n=6) discontinued due to insufficient activity; MRT-8102 interim Phase 1 data expected early 2026.","Updated MRT-2359 data to be presented at ASCO GU Symposium in February 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125782,"accession_number":"0001193125-25-268042","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Monte Rosa reports Q3 net loss $27.1M; second Novartis deal with $120M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $27.1M vs $23.9M YoY; collaboration revenue $12.8M (vs $9.2M).","Second Novartis agreement: $120M upfront, total eligible up to $5.7B for immune-mediated disease degraders.","Phase 1 NEK7 MGD MRT-8102 enrolling; initial data including high-CVD risk cohort on track for H1 2026.","Cash $396.2M at Sept. 30; raised $23.9M net from October ATM; runway through 2028.","MRT-2359 mCRPC data by year-end; CDK2/cyclin E1 IND submission targeted for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":120891000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142509,"accession_number":"0001193125-25-202760","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Monte Rosa and Novartis expand collaboration for immune-disease degraders; upfront $120M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Monte Rosa receives $120M upfront from Novartis under new collaboration for degraders in immune-mediated diseases.","Up to $5.7B in total milestone payments plus tiered royalties (high single to low double-digits) across up to three programs.","Novartis gets exclusive license to one undisclosed discovery target and options on two additional preclinical I&I programs.","Second collaboration with Novartis; first (VAV1/MRT-6160) was announced Oct 2024.","Extended cash runway accelerates preclinical and clinical-stage immunology pipeline; Phase 2 readouts expected for MRT-8102, MRT-6160, MRT-2359."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142508,"accession_number":"0000950170-25-104545","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Monte Rosa Q2 net loss narrows to $12.3M on $23.2M collaboration revenue; cash runway to 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue $23.2M (vs $4.7M YoY) from Novartis license; net loss improved to $12.3M from $30.3M.","R&D $30.7M, G&A $8.1M; cash $295.5M (down $35.5M from Q1), expected to fund into 2028.","Phase 1 of NEK7-directed MGD MRT-8102 dosed; initial data expected H1 2026 for inflammatory diseases.","MRT-6160 advancing toward multiple Phase 2 studies with Novartis; potential milestones up to $2.1B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":108123000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160548,"accession_number":"0000950170-25-086129","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Monte Rosa Therapeutics elects three Class I directors, ratifies auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Christine Siu, Kimberly Blackwell, and Jan Skvarka as Class I directors for three-year terms ending in 2028.","Christine Siu received 52.1M for, 3.4M withheld; Jan Skvarka received 44.8M for, 10.7M withheld.","Ratified Deloitte & Touche LLP as independent auditor for FY 2025 with 57.9M for, 139k against, 12.9k abstain.","Record date April 16, 2025; 61,509,821 shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160547,"accession_number":"0000950170-25-066370","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Monte Rosa Q1 net income $46.9M on Novartis revenue; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $46.9M vs net loss of $32.0M a year ago; collaboration revenue $84.9M from Novartis.","Cash, equivalents, and securities $331M; expected to fund operations into 2028.","MRT-6160 (VAV1) advancing to Phase 2 with Novartis; up to $2.1B in milestones.","MRT-2359 (GSPT1) shows clinical signals in CRPC; additional data expected H2 2025.","IND filing for MRT-8102 (NEK7) on track H1 2025; CDK2/CCNE1 IND planned for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":84929000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178794,"accession_number":"0000950170-25-042319","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Monte Rosa Q4 net income $13.4M; Ph1 MRT-6160 >90% VAV1 deg, MRT-2359 CRPC response","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net income $13.4M vs net loss $33.3M in Q4 2023; collaboration revenue $60.6M from Novartis/Roche deals.","Cash, equivalents, securities $377M as of Dec 31, 2024; expected to fund operations into 2028.","MRT-6160 Phase 1 showed >90% VAV1 degradation, favorable safety; path to Phase 2 with Novartis.","MRT-2359 in CRPC: confirmed partial response (-57%) in 1 of 3 evaluable patients; focus on CRPC moving forward.","MRT-8102 NEK7 degrader on track for IND H1 2025; GLP tox showed >200-fold safety margin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178793,"accession_number":"0000950170-25-003776","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Monte Rosa announces 2025 milestones and $377M cash position funding into 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents, and securities of $377.0M as of Dec 31, 2024; funds operations into 2028.","Initial Phase 1 SAD/MAD data for VAV1 degrader MRT-6160 expected Q1 2025; Novartis license deal gave $150M upfront.","Updated biomarker and activity data from MRT-2359 Phase 1/2 in MYC-driven solid tumors expected Q1 2025.","IND filing for NEK7 degrader MRT-8102 in H1 2025; CDK2 candidate nomination in H1 2025.","Second-generation NEK7 candidate with CNS penetration nomination in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195479,"accession_number":"0000950170-24-136042","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Monte Rosa Therapeutics appoints Eric A. Hughes, M.D., Ph.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Hughes is Executive VP, Global R&D and Chief Medical Officer at Teva Pharmaceuticals; previously at Vertex, Novartis, BMS.","Granted option to purchase 44,200 shares vesting monthly over 36 months; annual director fee of $40,000.","Also eligible for annual stock option grants of 22,100 shares after each annual meeting starting 2025.","Board determined Dr. Hughes is independent under Nasdaq standards; serves as Class III director until 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195478,"accession_number":"0000950170-24-133525","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Monte Rosa sets RP2D for MRT-2359 at 0.5 mg/day 21/7 schedule; safety, PD data positive","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RP2D selected: 0.5 mg daily on 21-days-on/7-days-off schedule based on favorable safety and ~60% GSPT1 degradation.","No hypotension, cytokine release syndrome, or clinically significant hypocalcemia observed at any dose.","Doses ≥1.5 mg/day on 5/9 schedule exceeded MTD; thrombocytopenia was DLT; 0.5 and 1 mg were tolerable.","Combination safety assessments started: MRT-2359 + enzalutamide in prostate cancer and + fulvestrant in breast cancer.","Updated biomarker and activity data from Phase 1/2 study expected in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195477,"accession_number":"0000950170-24-122766","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Monte Rosa reports Q3 net loss $23.9M; announces Novartis deal for VAV1 degraders with $150M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $23.9M for Q3 2024; collaboration revenue of $9.2M from Roche.","Global license with Novartis for VAV1 MGDs: $150M upfront, up to $2.1B milestones, U.S. P&L share.","MRT-6160 Phase 1 SAD/MAD ongoing; initial safety and PD data expected by Q1 2025.","MRT-2359 Phase 1/2 in MYC-driven tumors; updated results and Phase 2 guidance by year-end 2024.","Cash $247.1M at Sept 30; plus $150M Novartis upfront extends runway into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195476,"accession_number":"0000950170-24-117567","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Monte Rosa licenses VAV1 degrader MRT-6160 to Novartis for $150M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Novartis gets exclusive worldwide rights to develop, manufacture, and commercialize VAV1 MGDs including MRT-6160.","$150 million upfront payment; up to $2.1B in development, regulatory, and sales milestones starting at Phase 2.","Monte Rosa completes ongoing Phase 1 study; Novartis handles all subsequent development from Phase 2 onward.","Monte Rosa eligible for tiered royalties on ex-U.S. net sales and 30% U.S. profit/loss share from Phase 3 onward.","Deal validates Monte Rosa's QuEEN discovery engine and extends operational runway; closing subject to HSR clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211734,"accession_number":"0000950170-24-093294","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Monte Rosa Q2 net loss $30.3M; cash $267.1M; IND cleared for MRT-6160","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $30.3M for Q2 2024 vs $32.0M in Q1; collaboration revenue $4.7M from Roche deal.","Cash, equivalents, securities $267.1M at June 30, 2024; expected to fund operations into H1 2027.","IND accepted by FDA for VAV1-directed MGD MRT-6160; Phase 1 SAD/MAD to start summer with data expected Q1 2025.","MRT-2359 Phase 1/2 dose escalation ongoing at 0.75 mg 21/7 schedule; RP2D determination and updated results expected H2 2024.","Achieved first research milestones and payments from Roche collaboration; $100M public offering completed in May."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":5759000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230474,"accession_number":"0000950170-24-078159","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monte Rosa: MRT-2359 dose update; MRT-6160 IND for autoimmune diseases","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MRT-2359 Phase 1/2: favorable safety at 0.5 mg 21/7 schedule; evaluating 0.75 mg cohort; RP2D and updated data expected H2 2024.","IND submitted for MRT-6160, VAV1-directed MGD for systemic/neurological autoimmune diseases; Phase 1 SAD/MAD starts summer 2024 with data Q1 2025.","MRT-2359 potential RP2D of 0.5 mg using 21 days on/7 days off regimen, allowing twice as frequent dosing per cycle vs prior schedule.","MRT-6160 is first rationally designed MGD for non-oncology indication; preclinical efficacy in IBD, RA, MS models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230473,"accession_number":"0000950170-24-072407","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Monte Rosa Therapeutics 2024 annual meeting results: directors elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Markus Warmuth, M.D. elected with 39,473,886 votes for, 84,415 withheld; Ali Behbahani, M.D. with 23,794,947 for, 15,763,354 withheld.","Ratification of Deloitte & Touche LLP as independent auditor for FY 2024 approved: 40,409,003 for, 59,893 against, 3 abstentions.","No other matters were submitted to a vote at the June 12, 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230472,"accession_number":"0001193125-24-149802","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Monte Rosa Therapeutics promotes three executives to CSO, CBO/CLO, and COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sharon Townson, Ph.D., promoted to Chief Scientific Officer; previously CTO.","Phil Nickson, Ph.D., J.D., promoted to Chief Business and Legal Officer; previously General Counsel.","Jennifer Champoux promoted to Chief Operating Officer; previously Chief People and Operations Officer.","All promotions effective immediately as of May 30, 2024.","No departures announced; internal promotions reflect pipeline and platform advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230471,"accession_number":"0001193125-24-140533","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Monte Rosa prices $100M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 10.6M shares at $4.70/share and pre-funded warrants for 10.6M shares at $4.6999/warrant; gross proceeds $100M.","Net proceeds ~$96.7M; expected close May 20, 2024; led by Dimension and a life-sciences institutional investor.","Funds to advance MRT-6160, MRT-8102 clinical programs and QuEEN platform; cash runway into H1 2027.","Underwriters: TD Cowen and Wedbush PacGrow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230470,"accession_number":"0000950170-24-056253","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Monte Rosa Q1 net loss $32M; pipeline advances with MRT-2359, MRT-6160, MRT-8102 milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 net loss $32.0M; cash $197.8M (down from $237.0M Dec 2023), sufficient into H1 2026.","MRT-2359: RP2D determination expected Q2 2024, Phase 1 clinical data H2 2024, Phase 2 before year-end.","MRT-6160: IND submission Q2 2024, Phase 1 SAD/MAD study mid-2024, data Q1 2025; favorable GLP tox profile.","MRT-8102: NEK7-directed MGD shows CNS exposure in NHPs; IND on track for Q1 2025.","New CCNE1-directed MGD discovery program launched for previously undruggable oncology target."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1064000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230469,"accession_number":"0000950170-24-052055","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Monte Rosa CSO Owen Wallace departs May 17 to become CEO at UK biotech; remains adviser","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Owen Wallace resigns as CSO effective May 17, 2024, to become CEO of a UK-based biotech company.","Departure is not due to any disagreement with Monte Rosa or its board; will continue as scientific adviser on SAB.","Drug discovery led by Sharon Towson (CTO), John Castle (CDIO), and Magnus Walter (SVP Drug Discovery).","Company expects no disruption to ongoing MGD programs or drug discovery efforts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248859,"accession_number":"0000950170-24-031138","cik":1826457,"company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Monte Rosa reports Q4 2023 net loss $33.3M; cash into H1 2026; key pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $33.3M ($30.8M prior year); FY net loss $135.4M; cash $237M, runway into H1 2026.","MRT-2359 MYC-driven solid tumors Phase 1/2; recommended Phase 2 dose expected Q2 2024; Fast Track for SCLC and NSCLC.","MRT-6160 VAV1 MGD IND filing planned Q2 2024; Phase 1 SAD/MAD study start mid-2024.","MRT-8102 NEK7 program first development candidate nominated; IND submission targeted Q1 2025.","Entered Roche collaboration; $50M upfront, potential >$2B milestones plus royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1619470555.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}